Depressed Mood Improvement Through Nicotine Dosing 2
NCT04433767, Phase 2, Completed, Vanderbilt University Medical Center; results first posted 2023-12-06
Trial 12
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Depressed Mood Improvement Through Nicotine Dosing 2 | ClinicalTrials.gov |
| NCT number | NCT04433767 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 29 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Vanderbilt University Medical Center | ClinicalTrials.gov |
| Conditions | Depressive Disorder | ClinicalTrials.gov |
| Interventions | Transdermal Nicotine patch | ClinicalTrials.gov |
| First posted | 2020-06-16 | ClinicalTrials.gov |
| Last updated | 2023-12-06 | ClinicalTrials.gov |
| Results first posted | 2023-12-06 | ClinicalTrials.gov |
| Limitations and caveats | Small, open-label study design | ClinicalTrials.gov |
Registered outcomes 22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | MADRS (Montgomery Asberg Depression Rating Scale) Score Change | Baseline to week 12 | Primary mood outcome measured by the total score of the clinician rated MADRS. MADRS will be measured every 3 weeks (baseline, week 3, week 6, week 9, and week 12). MADRS total score range is 0-60, where higher scores indicate greater depression severity. Change is calculated as the difference between week 12 and baseline. | ClinicalTrials.gov |
| Primary | Number of Participants Exhibiting Reduction in Frontal Activation During the Emotional Stroop Task During Functional Magnetic Resonance Imaging (MRI) | Baseline, week 6, week 12 | MRI scans will be performed at baseline, week 6 and week 12. MRI will measure cognitive control network function, operationalized as a reduction in the emotional Stroop task functional MRI response in the middle and superior frontal gyri. The Stroop functional MRI response is calculated as the activation difference between incongruent and congruent conditions of the emotional Stroop task. The primary outcome is change in activation difference across the three time points. This is examined as a categorical variable, operationalized as those subjects who exhibit a middle / superior frontal gyri z-score reduction in activation over time of 0.5 or greater, relative to baseline at either week 6 and/or week 12. The a priori threshold being tested was that 60% or more of participants would exhibit a z-score reduction of 0.5 or greater, examined separately in the left and right middle and superior frontal gyri. | ClinicalTrials.gov |
| Secondary | NIH EXAMINER Test Battery Executive Composite Score Change | Baseline to week 12 | Secondary Cognitive Outcome: This neuropsychological test battery assesses a range of executive functions. Its Executive Composite Score is a single score that represents overall executive function performance across multiple individual neuropsychological tests, including the Dot counting test, the N-back test, the Flanker task, a continuous performance test, anti-saccades test, a set shifting test, and fluency tests. Higher scores indicate better executive function, with a range of -3.0 to 3.0. This composite is generated separately from EXAMINER sub scales. | ClinicalTrials.gov |
| Secondary | NIH EXAMINER Test Battery Cognitive Control Factor Change | Baseline to week 12 | Secondary Cognitive Outcome: This neuropsychological test battery assesses a range of executive functions. Its Cognitive Control Factor Score is a single score that represents cognitive control function performance across multiple individual neuropsychological tests, including the Flanker task, a continuous performance test, anti-saccades test, and a set shifting test. Higher scores indicate better executive function, with a range of -3.0 to 3.0. This is calculated independently of the executive composite or other factor scores. Secondary Cognitive Outcome: This neuropsychological test battery assesses a range of executive functions. We will examine its Executive Composite Score and the three factor scores (Cognitive Control, Fluency, and Working Memory). Higher scores indicate better performance. | ClinicalTrials.gov |
| Secondary | NIH EXAMINER Test Battery Fluency Factor Change | Baseline to week 12 | Secondary Cognitive Outcome: This neuropsychological test battery assesses a range of executive functions. Its Fluency Factor Score is a single score that represents verbal fluency performance across phonemic and categorical fluency assessments. Higher scores indicate better executive function, with a range of -3.0 to 3.0. This is calculated independently of the executive composite or other factor scores. | ClinicalTrials.gov |
| Secondary | NIH EXAMINER Test Battery Working Memory Factor Change | Baseline to week 12 | Secondary Cognitive Outcome: The EXAMINER test battery Working Memory Factor Score is a single score that represents working memory performance across multiple individual neuropsychological tests, including the Dot counting and n-back tests. Higher scores indicate better executive function, with a range of -3.0 to 3.0. This is calculated independently of the executive composite or other factor scores. Secondary Cognitive Outcome: This neuropsychological test battery assesses a range of executive functions. We will examine its Executive Composite Score and the three factor scores (Cognitive Control, Fluency, and Working Memory). Higher scores indicate better performance. | ClinicalTrials.gov |
| Secondary | Choice Reaction Time (CRT) Performance Change | Baseline to week 12 | Secondary cognitive outcome, a neuropsychological test measure of attention. We will examine change in total reaction time for the CRT. Lower reaction time indicates better performance. | ClinicalTrials.gov |
| Secondary | Selective Reminding Task Performance Change | Baseline to week12 | Secondary cognitive outcome, Selective Reminding Task as a test of immediate and delayed verbal memory. This is an 8-trial, 16-word test where the interviewer reads unrelated words to the participant who must recall them. Any missed items are then repeated before the next attempt. Scores range from 0-60, with higher scores indicating better performance. Change in the recall over 12 weeks reflect the verbal memory function, with higher scores indicating better verbal memory performance. | ClinicalTrials.gov |
| Secondary | Trait Adjectives Task, Change in Positive Items Endorsed | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Participants view a series of randomized, rapidly presented positive and negative characteristics and quickly indicate whether each adjective does or does not apply to them. Positive and negative adjectives are balanced. Measures include number of adjectives endorsed or rejected, and RT for those trials. These are assessed separately for positive items endorsed and negative items rejected. Task performance assesses self-referential negativity bias and is associated with antidepressant response. Task completed at baseline, week 6, and week 12. Scores for positive items endorsed range from 0 to 24, with higher scores indicating more positive items being endorsed, so a reduction in negativity bias. | ClinicalTrials.gov |
| Secondary | Trait Adjectives Task, Change in Negative Items Rejected | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Participants view a series of randomized, rapidly presented positive and negative characteristics and quickly indicate whether each adjective does or does not apply to them. Positive and negative adjectives are balanced. Measures include number of adjectives endorsed or rejected, and RT for those trials. These are assessed separately for positive items endorsed and negative items rejected. Task performance assesses self-referential negativity bias and is associated with antidepressant response. Task completed at baseline, week 6, and week 12. Scores for negative items rejected range from 0 to 24, with higher scores indicating that more negative items are rejected, thus a reduction in negativity bias. | ClinicalTrials.gov |
| Secondary | Trait Adjectives Task, Change in Reaction Time to Endorse Positive Items | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Participants view a series of randomized, rapidly presented positive and negative characteristics and quickly indicate whether each adjective does or does not apply to them. Positive and negative adjectives are balanced. Measures include number of adjectives endorsed or rejected, and RT for those trials. These are assessed separately for positive items endorsed and negative items rejected. Task performance assesses self-referential negativity bias and is associated with antidepressant response. Task completed at baseline, week 6, and week 12. A score reduction represents increased reaction time. | ClinicalTrials.gov |
| Secondary | Trait Adjectives Task, Change in Reaction Time to Reject Negative Items | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Participants view a series of randomized, rapidly presented positive and negative characteristics and quickly indicate whether each adjective does or does not apply to them. Positive and negative adjectives are balanced. Measures include number of adjectives endorsed or rejected, and RT for those trials. These are assessed separately for positive items endorsed and negative items rejected. Task performance assesses self-referential negativity bias and is associated with antidepressant response. Task completed at baseline, week 6, and week 12. A reduction in score indicates a faster reaction time. | ClinicalTrials.gov |
| Secondary | Ruminative Response Scale Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary mood outcome: Change in rumination measured by the Ruminative Response Scale total score measured at Screening visit, week 6 and week 12. This is a self-report scale with a range of 0-66, where higher scores indicate higher levels of rumination | ClinicalTrials.gov |
| Secondary | Apathy Evaluation Scale (AES) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary Mood Outcomes: Change in apathy as measured by the self-report AES, a questionnaire with a range of 0-54, where higher scores indicate greater apathy. Measured at baseline, week 6, and week 12. | ClinicalTrials.gov |
| Secondary | Insomnia Severity Index Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary Mood Outcomes: Change in the severity of insomnia measures as self-report , a questionnaire with the range of 0-21 ,where higher scores indicate increase in severity. Assessed at baseline, week 6, and week 12. | ClinicalTrials.gov |
| Secondary | Penn State Worry Questionnaire (PSWQ) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary mood outcome: Change in anxiety and worry measured by PSWQ, a self-report questionnaire with a range of 16-80, where higher scores indicate greater anxiety and worry. Assessed at baseline, week 6, and week 12. | ClinicalTrials.gov |
| Secondary | Fatigue Severity Scale Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary outcome examining fatigue using a self-report questionnaire that ranges from 0- 56, where higher scores indicate more severe fatigue. Questionnaire administered at baseline, week 6, and week 12. | ClinicalTrials.gov |
| Secondary | Dimensional Anhedonia Rating Scale (DARS) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary mood outcome: Change in anhedonia measured by DARS, a self-report questionnaire that ranges from 0-68, where lower scores indicate greater anhedonia. Conversely, higher scores indicate greater ability to enjoy activities. Assessed at baseline, week 6, and week 12. | ClinicalTrials.gov |
| Secondary | General Anxiety Disorder-7 Item Scale (GAD7) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary Mood outcome: self-reported questionnaire to measure the severity of anxiety. Questionnaire ranges 0-24, higher scores indicates greater anxiety state. Assessed at baseline, week 6, and week 12. | ClinicalTrials.gov |
| Secondary | Patient Reported Outcome Measurement Information System (PROMIS) Applied Cognition Abilities Short Form Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Secondary Cognitive outcome:PROMIS (Patient reported outcome measurement information system) is a self-reported questionnaire to measure mental acuity, concentration, verbal and nonverbal memory, verbal fluency, and perceived changes in these cognitive functions, ranges from 0-32 , where higher scores indicate improvement. Assessed at baseline, week 6, and week 12. | ClinicalTrials.gov |
Outcomes 22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | MADRS (Montgomery Asberg Depression Rating Scale) Score Change | Baseline to week 12 | Includes 29 participants randomized, 28 of whom completed all 12 weeks and 1 completed through week 6. | units on a scale | MEAN | ClinicalTrials.gov |
| PRIMARY | Number of Participants Exhibiting Reduction in Frontal Activation During the Emotional Stroop Task During Functional Magnetic Resonance Imaging (MRI) | Baseline, week 6, week 12 | Includes 29 participants randomized, 28 of whom completed all 12 weeks and 1 completed through week 6. | Participants | COUNT_OF_PARTICIPANTS | ClinicalTrials.gov |
| SECONDARY | NIH EXAMINER Test Battery Executive Composite Score Change | Baseline to week 12 | Analyses includes 28 randomized participants as 1 participant withdrew at week 6 so did not complete end of study assessments. | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | NIH EXAMINER Test Battery Cognitive Control Factor Change | Baseline to week 12 | Analyses includes 28 randomized participants as 1 participant withdrew at week 6 so did not complete end of study assessments. | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | NIH EXAMINER Test Battery Fluency Factor Change | Baseline to week 12 | Analyses includes 28 randomized participants as 1 participant withdrew at week 6 so did not complete end of study assessments. | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | NIH EXAMINER Test Battery Working Memory Factor Change | Baseline to week 12 | Analyses includes 28 randomized participants as 1 participant withdrew at week 6 so did not complete end of study assessments. | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Choice Reaction Time (CRT) Performance Change | Baseline to week 12 | Analyses includes 28 randomized participants as 1 participant withdrew at week 6 so did not complete end of study assessments. | Milliseconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Selective Reminding Task Performance Change | Baseline to week12 | Analyses includes 28 randomized participants as 1 participant withdrew at week 6 so did not complete end of study assessments. | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Trait Adjectives Task, Change in Positive Items Endorsed | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Trait Adjectives Task, Change in Negative Items Rejected | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | units on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Trait Adjectives Task, Change in Reaction Time to Endorse Positive Items | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | milliseconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Trait Adjectives Task, Change in Reaction Time to Reject Negative Items | Assessed at baseline, week 6, and week 12, change from baseline to week 12 reported | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | milliseconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Ruminative Response Scale Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Apathy Evaluation Scale (AES) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Insomnia Severity Index Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Penn State Worry Questionnaire (PSWQ) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Fatigue Severity Scale Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | 29 participants analyzed, although one participant withdrew at week 6 before trial completion. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Dimensional Anhedonia Rating Scale (DARS) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | General Anxiety Disorder-7 Item Scale (GAD7) Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | score on a scale | MEAN | ClinicalTrials.gov |
| SECONDARY | Patient Reported Outcome Measurement Information System (PROMIS) Applied Cognition Abilities Short Form Score Change | Assessed at baseline, week 6, and week 12; only change in baseline to week 12 reported. | Analyses includes 29 randomized participant, however 1 participant withdrew at week 6 so did not complete 12 week assessments. | score on a scale | MEAN | ClinicalTrials.gov |
Results by group 25
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| MADRS (Montgomery Asberg Depression Rating Scale) Score Change | Transdermal Nicotine Patch | -15.4 | Standard Deviation 6.7 | units on a scale | ClinicalTrials.gov | |
| Number of Participants Exhibiting Reduction in Frontal Activation During the Emotional Stroop Task During Functional Magnetic Resonance Imaging (MRI) | Transdermal Nicotine Patch | Left Middle Frontal Gyrus, total region | 18 | Participants | ClinicalTrials.gov | |
| Number of Participants Exhibiting Reduction in Frontal Activation During the Emotional Stroop Task During Functional Magnetic Resonance Imaging (MRI) | Transdermal Nicotine Patch | Left Superior Frontal Gyrus, Total region | 16 | Participants | ClinicalTrials.gov | |
| Number of Participants Exhibiting Reduction in Frontal Activation During the Emotional Stroop Task During Functional Magnetic Resonance Imaging (MRI) | Transdermal Nicotine Patch | Right Middle Frontal Gyrus, total region | 17 | Participants | ClinicalTrials.gov | |
| Number of Participants Exhibiting Reduction in Frontal Activation During the Emotional Stroop Task During Functional Magnetic Resonance Imaging (MRI) | Transdermal Nicotine Patch | Right Superior Frontal Gyrus, total region | 10 | Participants | ClinicalTrials.gov | |
| NIH EXAMINER Test Battery Executive Composite Score Change | Transdermal Nicotine Patch | 0.16 | Standard Deviation 0.31 | units on a scale | ClinicalTrials.gov | |
| NIH EXAMINER Test Battery Cognitive Control Factor Change | Transdermal Nicotine Patch | 0.29 | Standard Deviation 0.50 | units on a scale | ClinicalTrials.gov | |
| NIH EXAMINER Test Battery Fluency Factor Change | Transdermal Nicotine Patch | 0.18 | Standard Deviation 0.52 | units on a scale | ClinicalTrials.gov | |
| NIH EXAMINER Test Battery Working Memory Factor Change | Transdermal Nicotine Patch | 0.05 | Standard Deviation 0.69 | units on a scale | ClinicalTrials.gov | |
| Choice Reaction Time (CRT) Performance Change | Transdermal Nicotine Patch | -0.67 | Standard Deviation 123.40 | Milliseconds | ClinicalTrials.gov | |
| Selective Reminding Task Performance Change | Transdermal Nicotine Patch | 0.33 | Standard Deviation 16.61 | units on a scale | ClinicalTrials.gov | |
| Trait Adjectives Task, Change in Positive Items Endorsed | Transdermal Nicotine Patch | 2.28 | Standard Deviation 5.55 | units on a scale | ClinicalTrials.gov | |
| Trait Adjectives Task, Change in Negative Items Rejected | Transdermal Nicotine Patch | 1.92 | Standard Deviation 4.87 | units on a scale | ClinicalTrials.gov | |
| Trait Adjectives Task, Change in Reaction Time to Endorse Positive Items | Transdermal Nicotine Patch | -120.99 | Standard Deviation 228.89 | milliseconds | ClinicalTrials.gov | |
| Trait Adjectives Task, Change in Reaction Time to Reject Negative Items | Transdermal Nicotine Patch | -149.20 | Standard Deviation 252.25 | milliseconds | ClinicalTrials.gov | |
| Ruminative Response Scale Score Change | Transdermal Nicotine Patch | -7.32 | Standard Deviation 12.27 | score on a scale | ClinicalTrials.gov | |
| Apathy Evaluation Scale (AES) Score Change | Transdermal Nicotine Patch | -7.36 | Standard Deviation 8.91 | score on a scale | ClinicalTrials.gov | |
| Insomnia Severity Index Score Change | Transdermal Nicotine Patch | -4.50 | Standard Deviation 7.36 | score on a scale | ClinicalTrials.gov | |
| Penn State Worry Questionnaire (PSWQ) Score Change | Transdermal Nicotine Patch | -5.07 | Standard Deviation 22.39 | score on a scale | ClinicalTrials.gov | |
| Fatigue Severity Scale Score Change | Transdermal Nicotine Patch | -3.15 | Standard Deviation 14.0 | score on a scale | ClinicalTrials.gov |
Participant flow 3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | Transdermal Nicotine Patch | 29 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Transdermal Nicotine Patch | 28 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Transdermal Nicotine Patch | 1 | ClinicalTrials.gov |
Adverse events 8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|---|---|---|---|---|---|---|
| other | Skin reaction | Skin and subcutaneous tissue disorders | Transdermal Nicotine Patch | 13 | 29 | ClinicalTrials.gov | |
| other | Dizziness | Nervous system disorders | Transdermal Nicotine Patch | 5 | 29 | ClinicalTrials.gov | |
| other | Headache | Nervous system disorders | Transdermal Nicotine Patch | 5 | 29 | ClinicalTrials.gov | |
| other | Nausea | Gastrointestinal disorders | Transdermal Nicotine Patch | 5 | 29 | ClinicalTrials.gov | |
| other | Increased tension and inner restlessness | Psychiatric disorders | Transdermal Nicotine Patch | 3 | 29 | ClinicalTrials.gov | |
| other | Insomnia | Nervous system disorders | Transdermal Nicotine Patch | 3 | 29 | ClinicalTrials.gov | |
| other | Increased dream activity | Nervous system disorders | Transdermal Nicotine Patch | 3 | 29 | ClinicalTrials.gov | |
| serious | Fall | Injury, poisoning and procedural complications | Transdermal Nicotine Patch | 1 | 29 | 1 | ClinicalTrials.gov |
Adverse event totals 3
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | Transdermal Nicotine Patch | 0 | 29 | ClinicalTrials.gov |
| Total, other adverse events | Transdermal Nicotine Patch | 26 | 29 | ClinicalTrials.gov |
| Total, serious adverse events | Transdermal Nicotine Patch | 1 | 29 | ClinicalTrials.gov |
Papers 7
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 10
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Emotional Stroop Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Antisaccade Task | Secondary outcome | ConductCognition |
| Choice Reaction Time | Secondary outcome | ConductCognition |
| Continuous Performance Test | Secondary outcome | ConductCognition |
| Eriksen Flanker Task | Secondary outcome | ConductCognition |
| Selective Reminding Task | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)